CD274 and neoplasm: Moreover, a statistically significant advantage in OS was described despite histology (mOS 18.7 months in epithelioid histology and 18.1 months in non-epithelioid one), with a greater benefit versus chemotherapy in PD-L1 (≥1%) tumor positive expression (mOS 18.0 versus 13.3 months, HR 0.69) or in non-epithelioid tumors (mOS 18.1 versus 8.8 months, HR 0.46).